Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SAT1 | P21673 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810358 | 0.91 | EPHX2 (0.49) | EPHX2TDP1TSHRTET2KMT2A | |
| SCHEMBL9544427 | 0.90 | EPHX2 (0.51) | EPHX2TDP1KMT2AKDM4E | |
| SCHEMBL22096239 | 0.90 | EPHX2 (0.51) | EPHX2TDP1KMT2AKDM4E | |
| SCHEMBL4662750 | 0.90 | EPHX2 (0.51) | EPHX2TDP1KMT2AKDM4E | |
| SCHEMBL5232716 | 0.81 | GAA (0.48) | EPHX2TDP1SAT1SMN1; SMN2MGAM | |
| SCHEMBL16894162 | 0.81 | TET2 (0.36) | EPHX2TSHRTET2RECQLBRD4 | |
| SCHEMBL30028645 | 0.79 | KMT2A (0.41) | TDP1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL6018553 | 0.79 | KMT2A (0.36) | EPHX2TSHRRECQLBRD4SMN1; SMN2 | |
| SCHEMBL6018556 | 0.79 | KMT2A (0.36) | EPHX2TSHRRECQLBRD4SMN1; SMN2 | |
| SCHEMBL24197361 | 0.78 | BRD4 (0.50) | EPHX2TDP1TSHRBRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-109071497-B | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3419969-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| CN-109071497-A | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010034-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | EPHX2 681/4885TDP1 22/4885TSHR 3984/4885 |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | EPHX2 681/4885TDP1 22/4885TSHR 3984/4885 |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | EPHX2 681/4885TDP1 22/4885TSHR 3984/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | EPHX2 681/4885TDP1 22/4885TSHR 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.